Human pathology最新文献

Microinvasive Carcinoma of the Breast. 乳腺微型浸润性癌。

IF 2.7 2区医学

Human pathology Pub Date : 2025-06-20 DOI: 10.1016/j.humpath.2025.105856

Rachel Han, Edi Brogi

引用次数: 0

Evidence of interstitial continuity within and beyond the human pancreas 人类胰腺内外间质连续性的证据。

IF 2.7 2区医学

Human pathology Pub Date : 2025-06-18 DOI: 10.1016/j.humpath.2025.105855

Neil D. Theise , Mehran N. Kohnehshahri , Luis A. Chiriboga , Billie Fyfe , Wenqing Cao , Sui Zee , Rami Imam , Simona Pichler-Sekulic , Rebecca G. Wells

{"title":"Evidence of interstitial continuity within and beyond the human pancreas","authors":"Neil D. Theise , Mehran N. Kohnehshahri , Luis A. Chiriboga , Billie Fyfe , Wenqing Cao , Sui Zee , Rami Imam , Simona Pichler-Sekulic , Rebecca G. Wells","doi":"10.1016/j.humpath.2025.105855","DOIUrl":"10.1016/j.humpath.2025.105855","url":null,"abstract":"<div><div>Bodies have continuous reticular networks, comprising collagens and other extracellular matrix components, through all tissues and organs. We recently validated fluid flow through human interstitium and demonstrated that they are filled with hyaluronic acid by staining with biotinylated hyaluronic acid binding protein. Their continuity across tissue boundaries (skin and subcutis), and between organs (colon and mesentery) and along vessels (within adventitia) and nerves (within perineurium) has been demonstrated in this manner. We aim to evaluate the continuity of interstitium within human pancreas and beyond into adjoining tissues. Tissue blocks of histologically normal pancreas from nine pancreatectomy specimens were sectioned in parallel for staining with hematoxylin and eosin, Picrosirius red, and biotinylated hyaluronic acid binding protein. Also, specimens of invasive pancreatic cancer were assessed for interstitial tumor invasion. Picrosirius red ensheathes all microscopic units of the endocrine and exocrine pancreas, including acini, islets, and ducts, adventitia of blood vessels and perineurium, and into adjacent duodenum. Interstitial spaces within the fibrous tissue are filled with hyaluronic acid by staining and are also continuous through all microscopic structures of the pancreas, into adjoining duodenum and along vessels (within adventitia) and nerves (within perineurium). Invasive carcinoma is seen spreading through pre-existing interstitial spaces. Interstitium of the human pancreas is continuous within and beyond the pancreas. This continuity suggests the capacity to be a route of molecular, microbiome, and cellular trafficking and communication. In particular, it is a route of cancer spread.</div></div>","PeriodicalId":13062,"journal":{"name":"Human pathology","volume":"161 ","pages":"Article 105855"},"PeriodicalIF":2.7,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144336477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atypical Intraductal Proliferation (AIP) of the Prostate: Findings in Repeat Biopsy or Radical Prostatectomy in Patients who Met Pathologic Criteria for Active Surveillance. 非典型前列腺导管内增生（AIP）：在符合主动监测病理标准的患者中重复活检或根治性前列腺切除术的发现。

IF 2.7 2区医学

Human pathology Pub Date : 2025-06-14 DOI: 10.1016/j.humpath.2025.105854

Ruihe Lin, Huili Li, Ezra Baraban, Tamara Lotan, Angelo DeMarzo, Pedram Argani, Alexander Baras, Andres Matoso

{"title":"Atypical Intraductal Proliferation (AIP) of the Prostate: Findings in Repeat Biopsy or Radical Prostatectomy in Patients who Met Pathologic Criteria for Active Surveillance.","authors":"Ruihe Lin, Huili Li, Ezra Baraban, Tamara Lotan, Angelo DeMarzo, Pedram Argani, Alexander Baras, Andres Matoso","doi":"10.1016/j.humpath.2025.105854","DOIUrl":"https://doi.org/10.1016/j.humpath.2025.105854","url":null,"abstract":"The clinical significance of 'atypical intraductal proliferation' (AIP) is uncertain when found in prostate needle biopsy without intraductal carcinoma (IDC-P) or intermediate/high-grade prostate carcinoma (PCa). A retrospective review identified 168 patients diagnosed with AIP. Twenty-five (15%) were AIP alone, the rest with PCa. Follow-up biopsy or RP within 12 months was collected on patients with AIP-only, AIP and grade-group (GG)1, and AIP and GG2 PCa [<20% Gleason pattern 4 (GP4) without cribriform glands] who met pathologic criteria for active surveillance (AS). From 110 patients who met pathologic AS criteria, 66 did not have follow-up tissue. The findings among 28 patients with repeat biopsy were as follows: 14 (50%) were reclassified as a higher GG, including 3/6 (50%) from AIP-only [1 to GG1 and 2 to GG2 (60% and 20% GP4)], 8/16 from AIP/GG1 [50%, all to GG2 (1 with 30%, all others with <20% GP4)], 3/6 (50%) from AIP/GG2 (<20% GP4) [1 to GG3, and 2 to AIP/GG2 but with ≥20% GP4]. Five (18%) patients no longer met pathologic criteria for AS. Among patients with RP, 4 (33%) showed IDC-P. Quantitative and morphologic evaluation showed that higher number of cores, foci, and lumina in AIP with cribriform glands were more frequent in patients who were reclassified into higher grade-groups. In conclusion, AIP should be considered a potential marker for aggressive disease, warranting further evaluation. Although similar to IDC-P, it should remain a separate entity, as repeat biopsy does not show higher-than-expected AS exit rate.","PeriodicalId":13062,"journal":{"name":"Human pathology","volume":" ","pages":"105854"},"PeriodicalIF":2.7,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correlation with CD79B expression and clinicopathological parameters including cell of origin, CD79A and CD19 expression, and CD79B mutation in diffuse large B-cell lymphoma. 弥漫性大b细胞淋巴瘤中CD79B表达与临床病理参数（包括起源细胞、CD79A和CD19表达、CD79B突变）的相关性

IF 2.7 2区医学

Human pathology Pub Date : 2025-06-14 DOI: 10.1016/j.humpath.2025.105852

Yuto Kaimi, Maki Shibata, Suguru Fukuhara, Yuka Takahashi, Tetsuro Ochi, Shinichi Makita, Noriko Iwaki, Wataru Munakata, Koji Izutsu, Yasushi Yatabe, Akiko Miyagi Maeshima

{"title":"Correlation with CD79B expression and clinicopathological parameters including cell of origin, CD79A and CD19 expression, and CD79B mutation in diffuse large B-cell lymphoma.","authors":"Yuto Kaimi, Maki Shibata, Suguru Fukuhara, Yuka Takahashi, Tetsuro Ochi, Shinichi Makita, Noriko Iwaki, Wataru Munakata, Koji Izutsu, Yasushi Yatabe, Akiko Miyagi Maeshima","doi":"10.1016/j.humpath.2025.105852","DOIUrl":"10.1016/j.humpath.2025.105852","url":null,"abstract":"CD79B, the target of polatuzumab vedotin-an anti-CD79B antibody-drug conjugate-has shown greater efficacy in activated B-cell-type diffuse large B-cell lymphoma (DLBCL) than in germinal center B-cell (GCB) type. However, the correlation between CD79B expression and the clinicopathological parameters in DLBCL remains unknown. We evaluated CD79B expression using the H-score (range: 0-300) in 379 samples from 280 patients with DLBCL. Low CD79B expression (H-score ≤100) was observed in 48 samples (13 %), with 11 samples (3 %) showing no detectable expression. Notably, CD79B expression was significantly lower in the non-GCB type than in the GCB type (P < 0.001). Low CD79B expression correlated with advanced stage (P = 0.013), CD5 positivity (P = 0.014), and immunoblastic type (P = 0.067). Among the 48 DLBCL samples with low CD79B expression, 90 % demonstrated high (H-score >100) CD79A and CD19 expression. No mutation in the first tyrosine residue of CD79B immunoreceptor tyrosine-based activation motif, Y196, was identified in DLBCL with low CD79B expression. Additionally, low CD79B expression was not associated with the co-occurrence of CD79B ITAM and MYD88 L265P mutations (P = 0.748). Of the 78 patients with multiple biopsy specimens obtained from multiple sites or recurrent tumors, a change in CD79B expression from low to high or verse versa was observed in 9 % of patients. In conclusion, CD79B expression was lower in the non-GCB type than in the GCB type. CD79B, CD79A, and CD19 expressions were not completely correlated, and one expression cannot predict the others. In 9 % of patients, CD79B expression was inconsistent in multiple biopsy samples.","PeriodicalId":13062,"journal":{"name":"Human pathology","volume":" ","pages":"105852"},"PeriodicalIF":2.7,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TROP2 is highly expressed in cutaneous squamous cell carcinomas and a subset of adnexal carcinomas: A potential therapeutic target with TROP2-directed antibody drug conjugates. TROP2在皮肤鳞状细胞癌和附件癌中高表达：TROP2导向抗体药物偶联物的潜在治疗靶点。

IF 2.7 2区医学

Human pathology Pub Date : 2025-06-14 DOI: 10.1016/j.humpath.2025.105853

Lin J He, Yunyi Wang, Jonathan L Curry, Jing Ning, Phyu P Aung, Priyadharsini Nagarajan, Victor G Prieto, Carlos A Torres-Cabala, Woo Cheal Cho

{"title":"TROP2 is highly expressed in cutaneous squamous cell carcinomas and a subset of adnexal carcinomas: A potential therapeutic target with TROP2-directed antibody drug conjugates.","authors":"Lin J He, Yunyi Wang, Jonathan L Curry, Jing Ning, Phyu P Aung, Priyadharsini Nagarajan, Victor G Prieto, Carlos A Torres-Cabala, Woo Cheal Cho","doi":"10.1016/j.humpath.2025.105853","DOIUrl":"10.1016/j.humpath.2025.105853","url":null,"abstract":"Trophoblast cell surface antigen 2 (TROP2) has emerged as a promising therapeutic target in oncology. TROP2-directed antibody-drug conjugates (ADCs) are now approved for treating advanced malignancies such as breast carcinomas by the Food and Drug Administration. However, the expression patterns and potential therapeutic relevance of TROP2 in cutaneous neoplasms remain largely unexplored. In this study, we evaluated TROP2 expression by immunohistochemistry in 198 cutaneous tumors, including squamous cell carcinomas (SCCs; n = 44), basal cell carcinomas (BCCs; n = 27), Merkel cell carcinomas (MCCs; n = 12), melanomas (n = 25), atypical fibroxanthomas/pleomorphic dermal sarcomas (AFXs/PDSs; n = 17), and various adnexal (n = 58) and mesenchymal (n = 15) neoplasms. H-scores were calculated to quantify expression levels. TROP2 was consistently expressed in all SCCs (100 %; median H-score: 272.5) and in nearly all adnexal tumors (98 %; 57/58). In contrast, TROP2 expression was minimal or absent in BCCs, MCCs, melanomas, AFXs/PDSs, and mesenchymal neoplasms. Among adnexal tumors, at least moderately positive (H-score >100) TROP2 expression was observed in endocrine mucin-producing sweat gland carcinomas (n = 6; median: 170), sebaceous carcinomas (n = 6; median: 140), trichilemmal carcinomas (n = 2; median: 220), and individual cases of porocarcinoma, hidradenocarcinoma, pilomatrical carcinoma, and squamoid eccrine ductal carcinoma (H-scores: 280-295). Statistical analysis revealed significant differences in TROP2 expression among five major tumor groups (p < 0.001). Our study suggests that TROP2 immunohistochemical expression may have diagnostic utility and that TROP2-directed ADCs could offer therapeutic benefit to patients with advanced cutaneous SCCs and select adnexal carcinomas.","PeriodicalId":13062,"journal":{"name":"Human pathology","volume":" ","pages":"105853"},"PeriodicalIF":2.7,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atypical intraductal proliferation (AIP) of the prostate: Findings in repeat biopsy or radical prostatectomy in patients who met pathologic criteria for active surveillance. 非典型前列腺导管内增生（AIP）：在符合主动监测病理标准的患者中重复活检或根治性前列腺切除术的发现。

IF 2.7 2区医学

Human pathology Pub Date : 2025-06-13 DOI: 10.1016/j.humpath.2025.105841

Ruihe Lin, Huili Li, Ezra Baraban, Tamara Lotan, Angelo DeMarzo, Pedram Argani, Alexander Baras, Andres Matoso

{"title":"Atypical intraductal proliferation (AIP) of the prostate: Findings in repeat biopsy or radical prostatectomy in patients who met pathologic criteria for active surveillance.","authors":"Ruihe Lin, Huili Li, Ezra Baraban, Tamara Lotan, Angelo DeMarzo, Pedram Argani, Alexander Baras, Andres Matoso","doi":"10.1016/j.humpath.2025.105841","DOIUrl":"https://doi.org/10.1016/j.humpath.2025.105841","url":null,"abstract":"The clinical significance of 'atypical intraductal proliferation' (AIP) is uncertain when found in prostate needle biopsy without intraductal carcinoma (IDC-P) or intermediate/high-grade prostate carcinoma (PCa). A retrospective review identified 168 patients diagnosed with AIP. Twenty-five (15 %) were AIP alone, the rest with PCa. Follow-up biopsy or RP within 12 months was collected on patients with AIP-only, AIP and grade-group (GG)1, and AIP and GG2 PCa [<20 % Gleason pattern 4 (GP4) without cribriform glands] who met pathologic criteria for active surveillance (AS). From 110 patients who met pathologic AS criteria, 66 did not have follow-up tissue. The findings among 28 patients with repeat biopsy were as follows: 14 (50 %) were reclassified as a higher GG, including 3/6 (50 %) from AIP-only [1 to GG1 and 2 to GG2 (60 % and 20 % GP4)], 8/16 from AIP/GG1 [50 %, all to GG2 (1 with 30 %, all others with <20 % GP4)], 3/6 (50 %) from AIP/GG2 (<20 % GP4) [1 to GG3, and 2 to AIP/GG2 but with ≥20 % GP4]. Five (18 %) patients no longer met pathologic criteria for AS. Among patients with RP, 4 (33 %) showed IDC-P. Quantitative and morphologic evaluation showed that higher number of cores, foci, and lumina in AIP with cribriform glands were more frequent in patients who were reclassified into higher grade-groups. In conclusion, AIP should be considered a potential marker for aggressive disease, warranting further evaluation. Although similar to IDC-P, it should remain a separate entity, as repeat biopsy does not show higher-than-expected AS exit rate.","PeriodicalId":13062,"journal":{"name":"Human pathology","volume":" ","pages":"105841"},"PeriodicalIF":2.7,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of a novel surrogate panel for classifying human colorectal carcinomas according to consensus molecular subtypes. 根据一致的分子亚型对人类结直肠癌进行分类的新型替代面板的评估。

IF 2.7 2区医学

Human pathology Pub Date : 2025-06-11 DOI: 10.1016/j.humpath.2025.105840

Priyanka Mani, Lalita Mehra, Rakesh Deepak, Ashok Tiwari, Sunil Kumar, Chethan R, Rimlee Dutta, Nihar R Dash, Rajni Yadav, S V S Deo, Prasenjit Das

{"title":"Evaluation of a novel surrogate panel for classifying human colorectal carcinomas according to consensus molecular subtypes.","authors":"Priyanka Mani, Lalita Mehra, Rakesh Deepak, Ashok Tiwari, Sunil Kumar, Chethan R, Rimlee Dutta, Nihar R Dash, Rajni Yadav, S V S Deo, Prasenjit Das","doi":"10.1016/j.humpath.2025.105840","DOIUrl":"https://doi.org/10.1016/j.humpath.2025.105840","url":null,"abstract":"Clinical triaging of colorectal carcinomas (CRCs) is essential for prognostication and therapeutic decision-making. Consensus Molecular Subtyping (CMS) was developed for this purpose; however, it requires comprehensive genomic and transcriptomic studies and prediction algorithms, restricting its usage. We examined the utility of a limited surrogate panel of markers for classifying CRCs. We investigated the expression of immunohistochemical markers MLH1, PMS2, MSH2, MSH6, CDX2, HTRB2, FRMD6, and GLUT1, along with reverse transcriptase polymerase chain reaction for KRAS mutation in a retrospective cohort of 100 CRCs. MMR-deficient cases were classified as CMS1. Differential expressions of other markers, alongside consideration of KRAS mutation status as per CMS guidelines, were utilized to classify the tumors into three additional groups. A significant correlation was observed between tumor subtypes and TNM stage groups (P 0.04). While most stage I and II tumors were CMS1 (77.1 %, n-27/35) and CMS2 tumors (91.7 %, n-11/12), stage III and IV tumors were mostly CMS3 (50 %, n-6/12) and CMS4 (44.8 %, n = 13/29) tumors. Our algorithm classified the CRCs into prognostically favorable CMS2/CMS3 types, then unfavorable CMS1/CMS4 types. Notably, However, overall survival and disease-free survivals did not differ as per the individual CMS types. This study highlights the potential of surrogate tumor typing for clinical triaging. However, further research, building on the findings of this study and existing IHC-based classifiers, is essential to develop a more effective and practical surrogate classifier.","PeriodicalId":13062,"journal":{"name":"Human pathology","volume":" ","pages":"105840"},"PeriodicalIF":2.7,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

INSM1: A highly sensitive marker for primary and metastatic Merkel cell carcinoma, superior to SOX11, pancytokeratin, and CK20. INSM1：原发性和转移性默克尔细胞癌的高度敏感标志物，优于SOX11、全细胞角蛋白和CK20。

IF 2.7 2区医学

Human pathology Pub Date : 2025-06-11 DOI: 10.1016/j.humpath.2025.105838

Jeongeun Do, Yunyi Wang, Phyu P Aung, Priyadharsini Nagarajan, Jing Ning, Jonathan L Curry, Doina Ivan, Volha Lenskaya, Carlos A Torres-Cabala, Victor G Prieto, Woo Cheal Cho

{"title":"INSM1: A highly sensitive marker for primary and metastatic Merkel cell carcinoma, superior to SOX11, pancytokeratin, and CK20.","authors":"Jeongeun Do, Yunyi Wang, Phyu P Aung, Priyadharsini Nagarajan, Jing Ning, Jonathan L Curry, Doina Ivan, Volha Lenskaya, Carlos A Torres-Cabala, Victor G Prieto, Woo Cheal Cho","doi":"10.1016/j.humpath.2025.105838","DOIUrl":"https://doi.org/10.1016/j.humpath.2025.105838","url":null,"abstract":"Detection of Merkel cell carcinoma (MCC) micrometastases in sentinel lymph nodes (SLNs) often necessitates immunohistochemical studies like pancytokeratin (panCK) or CK20. However, panCK can label non-epithelial cells, particularly dendritic reticulum cells, complicating interpretation, while CK20 is absent in up to 24 % of MCCs, leading to potential false negatives. Recent evidence suggests SOX11 and INSM1 as sensitive nuclear neuroendocrine markers, though their comparative performance in this setting remains unclear. We assessed the expression of panCK (AE1/AE3, CK8/18, Cam5.2, and MNF116), CK20, SOX11, and INSM1 in 25 primary MCCs and 8 nodal metastases. SOX11 and INSM1 demonstrated the highest median H-scores (both 297), significantly outperforming panCK and CK20 (both 255) (p < 0.001). Although median H-scores for SOX11 and INSM1 were similar, 9 % (3/33) of cases lacked SOX11 expression. Direct comparison revealed significant differences in proportion and median H-score between SOX11 and INSM1 (p = 0.020 and p = 0.012, respectively), while intensity did not differ significantly (p = 0.317). When used alongside panCK, INSM1 yielded the highest combined sensitivity (100 %), surpassing panCK/CK20 and panCK/SOX11 combinations. These findings support the use of a panCK/INSM1 panel as a highly sensitive approach for detecting MCC micrometastases in SLNs. While INSM1 demonstrates robust performance, interpretation must account for background immunoreactivity in hematolymphoid elements, a possible and important diagnostic pitfall when using this marker in clinical practice. Further prospective studies with larger and more diverse cohorts may be needed to confirm these results and refine the optimal immunohistochemical strategy for MCC detection in SLNs.","PeriodicalId":13062,"journal":{"name":"Human pathology","volume":" ","pages":"105838"},"PeriodicalIF":2.7,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Female reproductive tract inflammatory myofibroblastic tumor (IMT): A comprehensive analysis of clinicopathological and genomic features in a case series, including the identification of SERPINE1-ALK fusion in the fallopian tube. 女性生殖道炎症性肌纤维母细胞瘤（IMT）：临床病理和基因组特征的综合分析，包括输卵管SERPINE1-ALK融合的鉴定。

IF 2.7 2区医学

Human pathology Pub Date : 2025-06-11 DOI: 10.1016/j.humpath.2025.105839

Ting Lei, Bingbing Liu, Yani Wei, Yongqiang Shi, Wei Zhao, Yuqing Cheng, Haiyan Wang, Fenghua Zhang, Dachuan Zhang, Qing Li, Xian Qiang

{"title":"Female reproductive tract inflammatory myofibroblastic tumor (IMT): A comprehensive analysis of clinicopathological and genomic features in a case series, including the identification of SERPINE1-ALK fusion in the fallopian tube.","authors":"Ting Lei, Bingbing Liu, Yani Wei, Yongqiang Shi, Wei Zhao, Yuqing Cheng, Haiyan Wang, Fenghua Zhang, Dachuan Zhang, Qing Li, Xian Qiang","doi":"10.1016/j.humpath.2025.105839","DOIUrl":"10.1016/j.humpath.2025.105839","url":null,"abstract":"Inflammatory myofibroblastic tumors (IMTs) of the female reproductive tract are rare neoplasms, predominantly originating in the uterus, but can occasionally be identified in other locations. This retrospective study included 15 cases from six hospitals in China between 2017 and 2024, comprising 14 cases involving the uterus and one involving a fallopian tube. DNA and RNA next-generation sequencing (NGS) was conducted on all samples. The age of onset ranged from 34 to 54 years, with a median of 41 years and a mean of 42.40 ± 1.32 years. Tumor sizes varied from 2.9 cm to 10.0 cm, with a median size of 6.00 cm and a mean size of 5.90 ± 0.45 cm. RNA sequencing demonstrated ALK rearrangements with either identical or distinct fusion partners in individual cases, including a new partner, SERPINE1, detected in the case involving the fallopian tube. DNA sequencing revealed that 46.7 % (7/15) of the cases exhibited additional gene mutations, including one case with a TP53 mutation that had been previously reported and subsequently developed metastasis within a few months. ALK rearrangement remains the primary driver gene and therapeutic target for this type of tumor. From the perspective of predicting tumor biology, genetic variations at the DNA level, in addition to clinicopathological parameters, are equally significant and may provide a critical foundation for prognosis.","PeriodicalId":13062,"journal":{"name":"Human pathology","volume":" ","pages":"105839"},"PeriodicalIF":2.7,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic models for breast cancer: A narrative review. 乳腺癌预后模型：叙述性综述。

IF 2.7 2区医学

Human pathology Pub Date : 2025-06-11 DOI: 10.1016/j.humpath.2025.105835

Hua Guo, Shi Wei

引用次数: 0